Tongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However， the therapeutic benefits of chemotherapy are usually attenuated due to intrinsic and/or acquired drug resistance， and a large proportion of TSCC are resistant to chemotherapy， which may result in more aggressive tumor behavior and an even worse clinical outcome. Recently， the potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise， but miRNAs with predictive value remain to be identified and underlying mechanisms remain to be unders... More